

Non small cell lung Cancer



Every patient with locoregional NSCLC should be approached as a potential candidate for surgery

5-year Survival




Lung Cancer


T= Primary Tumor


N=Lymph Node

M= Metastasis



pStage I






5-yrs survival: 67%


5-yrs survival: 57%


pTNM Staging

Stage I: All T1-T2 and N0 tumors



pStage II






5-yrs survival: 55%


5-yrs survival: 39%

pTNM Staging

Stage II: T1-T2 and N1 and T3 N0 tumors



Type surgery & outcome



Mortality (%):

Morbidity (%):

Higher Stages

Stage IIIA: T3N1 or any T1-3N2

Stage IIIB: T4 or N3


Stage IV: Unresectable disease

(except solitary brain and

adrenal mts)

Multimodality Therapy

Multidisciplinary approach



Complete Resection


Surgeon is morally certain he or she has encompassed all tumor disease


Proximal margins of resected specimen are microscopically free of tumor

Within each major lymphatic drainage region, the most distal node is microscopically tumor free

Capsules of resected nodes are intact

Principles of Surgical Oncology





Principles of Surgical Oncology



14 days
Restoration of
cellular immunity
Post-thoracotomy

Day 21
Restored cellular
immunity to tumorassociated antigens

Surgery

Day 4
Restoration of cellular immunity
Post-MIC

Day 21
Restoration of delayed-type hypersensitivity response

Immunological "window of opportunity"

N2 Tumors


Cure Rate

N0


N2

50-80%


10-30%




Nodes Mets Pathway (Right)





Nodes Mets Pathway (Left)



N2 Tumors









Multiple levels of involvement Nodal vs. extranodal disease Superior vs. inferior mediastinum Bulky clinical vs. minimal CT nodes Only 20% of N2 are resectable

T3-4 Tumors

Tumors invading any mediastinal structures or organs

Pancoast Tumors





Shaw-Paulson

Pancoast Results


Authors	No	5-yrs survival (%)	Mortality
Paulson <i>et al.</i> (1986)	79	35	3
Ginsberg et al. (1994)	100	26	4
Dartevelle et al. (1998)	70	34	-
Rusch et al. (2001)	111	70 CR (2-yr)	2.7
Wright <i>et al.</i> (2002)	35	84 (4-yrs)	_

Hannover Intrathoracic Study Group: Phase II study


- Carboplatin (AUC2) and paclitaxel (40 mg/m² days 1, 8, 15, 22, 29) & RT (45 Gy week 1-5, day 1-5);
- 30 patients were evaluable;
- Complete resection in 100%, 43% of them pathological CR to induction treatment;
- The actuarial 3-year survival is 52% and the median survival has not been reached yet




• Lobectomy can be done via anterior approach <u>alone</u>




Operations for intrathoracic vessels




Vascular T4 NSCLC






Vascular T4 NSCLC




Vascular T4 NSCLC





Airway T4 NSCLC



ORIGINAL ARTICLE: GENERAL THORACIC

Technical Innovations of Carinal Resection for Nonsmall-Cell Lung Cancer

Paolo Macchiarini, MD, PhD, Matthias Altmayer, MD, Tetsuhiko Go, MD, Thorsten Walles, MD, Karl Schulze, MD, Ingeborg Wildfang, MD, Axel Haverich, MD, PhD, Michael Hardin, PhD, and the Hannover Interdisciplinary Intrathoracic Tumor Task Force Group

Department of General Thoracic Surgery, University of Barcelona, Spain; Department of Cardiothoracic and Vascular Surgery, Hannover Medical School, Hannover, Germany; Department of Thoracic Surgery, Fukuiken Saiseikai Hospital, Fukui City, Japan; Departments of Anesthesiology and Radiation Oncology, Siloah Hospital, Hannover, Germany; and Information Systems, Statistics, and Management Science. University of Alabama. Tuscaloosa, Alabama

Background. We present our perioperative management of operable nonsmall-cell lung cancer invading the tracheobronchial bifurcation and the results obtained.

Methods. Fifty consecutive patients undergoing carinal surgery with radical lymphadenectomy over a 5-year period were studied.

Results. Eighteen patients (36%) were N2 and had chemoradiation (48 ± 6 Gy) preoperatively. Surgery included 34 carinal pneumonectomies (24 right, 10 left), 11 carinal lobectomies (n = 6) or bilobectomies (n = 5), and 5 carinal resections, with (n = 3) and without (n = 2) reconstructions. Patients were ventilated through low tidal volume controlled techniques except during airway resection and reconstruction, during which the apnelic (hyper) oxygenation techniques were used. High inspiratory oxygen concentrations, multiple collapse and reexpansions, hypoperfusion of the ipsilateral lung, and fluid overload were avoided. All patients but 1 were extubated in the operating room, 7 ± 5 minutes after skin closure. Operative mortality (less than 30 days) and morbidity

were 4% (n = 2) and 37% (n = 18), respectively. All R1 resections but 1 (98%) were complete. The number of resected nodes per patient was 9 \pm 2, and 7 (22%) of the 32 patients who had negative preoperative positron emission tomography results had micrometastatic mediastinal nodes. With a median follow-up of 38 months, actuarial 5-year and disease-free survivals were 51% and 47%, respectively. Disease-free survival was significantly affected by endobronchial extension (tracheobronchial angle invasion versus less than 0.5 cm from carina, p = 0.03) and nodal status (N0 versus N1-2, p = 0.02) in the multivariate analysis.


Conclusions. Preoperative chemoradiation, carinal lobectomy, or left pneumonectomy, and radical lymphadenectomy do not worsen the therapeutic index of carinal surgery. The high incidence of micrometastatic nodes in positron emission tomography-negative patients claims AQ:1 routine mediastinoscopy and radical lymphadenectomy. (Ann Thorac Surg 2006;xx:xxx)

© 2006 by The Society of Thoracic Surgeons

Study Design

Eligibility: (Stages IIIB)

Node-negative



Surgery

Node-positive

Mediastinoscopy

Chemoradiation

(Carboplatin/Taxol + 45 Gy)

No-Redo mediastinoscopy

Surgery

Surgical outcome

Operative

Mortality

1 (3%)


Morbidity

14 (39%

Major

10 Minor

Neoadjuvant vs. not p=0.027



Oncological outcome

- All but 1 had a R0 resection;
- 39% of pretreated N2 pts were pathologically downstaged to N1 or N0;
- PET scan was false negative in 7 (32%);
- Multivariate DFS analysis: endobronchial extension (<0.5 cm from carina vs. tracheobronchial angle) and N status (N0 vs. N1 & N2)

Conclusions

